Finanzen von IRIDEX Corp (IRIX)IRIXIRIDEX Corp

IRIDEX Corp (IRIX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Retina, accounting for 49.4% of total sales, equivalent to $5.83M. Other significant revenue streams include G6 and Other. Understanding this composition is critical for investors evaluating how IRIX navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, IRIDEX Corp maintains a gross margin of 34.19%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8.19%, while the net margin is -10.07%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IRIX converts its operational activities into shareholder value.

In the context of the broader market, IRIX competes directly with industry leaders such as SINT and CTSO. With a market capitalization of $11.87M, it holds a significant position in the sector. When comparing efficiency, IRIX's gross margin of 34.19% stands against SINT's 61.50% and CTSO's 73.18%. Such benchmarking helps identify whether IRIDEX Corp is trading at a premium or discount relative to its financial performance.

IRIDEX has reported consistent net losses, with a net loss of $1.3 million in Q2 2026, and a gross margin that has fluctuated, currently at 34.19%. Total revenue for Q2 2026 was $12.6 million, a 7% decrease year-over-year, indicating declining sales performance.